Effects of Xuezhikang in patients with dyslipidemia: a multicenter, randomized, placebo-controlled study
| Autor: | Harold E. Bays, Ping Lan Liu, Simon Li, Zhenwen Duan, Shui-ping Zhao, Alan J. Reichman, Osvaldo A. Brusco, Junxian Zhao, Guoping Lu, David M. Capuzzi, Yan Zhang, Shuren Guo, Patrick M. Moriarty, Sam Lerman, Ping Ye, Fumin Zhang, Adam Karns, Shaowen Liu, Eli M. Roth, Yuhua Liao |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Adult
Male medicine.medical_specialty China Gastrointestinal Diseases Endocrinology Diabetes and Metabolism Placebo-controlled study Placebo Gastroenterology Placebos chemistry.chemical_compound Internal medicine Internal Medicine medicine Red yeast rice Humans In patient Lovastatin Apolipoproteins A Triglycerides Aged Apolipoproteins B Dyslipidemias Hypolipidemic Agents Biological Products Nutrition and Dietetics business.industry Cholesterol Cholesterol HDL Cholesterol LDL Middle Aged medicine.disease Coronary heart disease United States Endocrinology chemistry lipids (amino acids peptides and proteins) Female Cardiology and Cardiovascular Medicine business Dyslipidemia medicine.drug Drugs Chinese Herbal |
| Zdroj: | Journal of clinical lipidology. 8(6) |
| ISSN: | 1933-2874 |
| Popis: | Xuezhikang (XZK) is an extract of fermented red yeast rice that has lipid-lowering properties.To evaluate the effects of XZK on lipids in subjects with dyslipidemia but no coronary heart disease.A total of 116 adults with baseline non-high-density lipoprotein cholesterol (non-HDL-C) levels of approximately 208 mg/dL and low-density lipoprotein cholesterol (LDL-C) levels of approximately 175 mg/dL were randomized to either placebo or XZK 1200 or 2400 mg daily and treated for 12 weeks.A majority of the patients were white (53.4%) or Asian (37.1%). Daily XZK 1200 mg and 2400 mg for 4 to 12 weeks resulted in statistically significant (P .001) and clinically meaningful decreases in non-HDL-C (∼24% reduction) and LDL-C (∼27% reduction) compared with placebo. XZK treatment at either dose enabled approximately 50% of subjects to reduce their LDL-C levels by ≥ 30%. Doubling the XZK daily dose from 1200 to 2400 mg at treatment week 8 caused an additional 4.6% reduction in LDL-C. Significant benefits were also observed across secondary efficacy variables, including total cholesterol (TC), apolipoprotein B (Apo B), triglycerides, HDL-C, the TC/HDL-C ratio, and the Apo B/Apo A-I ratio, at treatment week 8 or 12. XZK was safe and well tolerated. Safety and tolerability profiles were similar across treatment groups. Most adverse events were gastrointestinal. No subject experienced myopathy or markedly elevated liver transaminases or creatine kinase.Xuezhikang significantly reduced non-HDL-C and LDL-C, and was well tolerated. Further, longer-term studies in more diverse patient populations are needed to corroborate these findings. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect